NYSEARCA:BBC Virtus LifeSci Biotech Clinical Trials ETF (BBC) Price, Holdings, & News $29.24 +0.45 (+1.56%) (As of 11/4/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisChartHoldingsRatings About Virtus LifeSci Biotech Clinical Trials ETF (NYSEARCA:BBC) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get BBC alerts:Sign Up Key Stats Today's Range$29.24▼$29.4150-Day Range$26.67▼$30.5552-Week Range$16.91▼$31.99Volume473 shsAverage Volume3,006 shsMarket Capitalization$11.70 millionAssets Under Management$11.50 millionDividend Yield0.30%Net Expense Ratio0.79%Aggregate RatingModerate Buy ETF OverviewThe Virtus LifeSci Biotech Clinical Trials ETF (BBC) is an exchange-traded fund that mostly invests in health care equity. The fund tracks an equally weighted index of US-listed biotech companies with lead drugs in various phases of clinical trials. BBC was launched on Dec 16, 2014 and is managed by Virtus.Read More… Top 10 AI Stocks to Buy Now (Ad)Are you ready to capitalize on the booming AI market? Our experts have identified the top 10 AI stocks set to skyrocket.Download our free report today Virtus LifeSci Biotech Clinical Trials ETF ExpensesTypeBBCHealth Care ETFsEquity ETFsNYSEARCA ETFsAll ETFsManagement Fee0.79%0.56%0.55%0.51%0.52%Other Expenses0.00%0.33%0.49%0.58%0.53%Total Expense0.79%0.71%0.71%0.73%0.71%Fee Waiver0.00%-0.45%-0.52%-0.67%-0.57%Net Expense0.79%0.61%0.61%0.58%0.59% Receive BBC Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Virtus LifeSci Biotech Clinical Trials ETF and its competitors with MarketBeat's FREE daily newsletter. Email Address BBC ETF News HeadlinesFDA Set To Approve COVID-19 Vaccines As Soon As This Week: Stocks, ETFs To WatchAugust 19, 2024 | benzinga.comTech ETFs on the Rise After Four Weeks in Deep RedAugust 19, 2024 | theglobeandmail.comBlackrock’s Sending THIS Crypto Higher on PurposeIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this surge is a massive new blockchain development…November 5, 2024 | Crypto 101 Media (Ad)Virtus Lifesci Biotech Products Etf Share ChatJuly 20, 2024 | lse.co.ukVirtus Lifesci Biotech Clinical Trials Etf Share ChatJuly 20, 2024 | lse.co.ukDrama at Trump trial as judge reprimands witness and clears courtMay 22, 2024 | bbc.comSee More Headlines BBC ETF - Frequently Asked Questions How have BBC shares performed this year? Virtus LifeSci Biotech Clinical Trials ETF's stock was trading at $24.45 at the beginning of 2024. Since then, BBC stock has increased by 19.6% and is now trading at $29.24. View the best growth stocks for 2024 here. How do I buy shares of Virtus LifeSci Biotech Clinical Trials ETF? Shares of BBC stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Virtus LifeSci Biotech Clinical Trials ETF own? Based on aggregate information from My MarketBeat watchlists, some other companies that Virtus LifeSci Biotech Clinical Trials ETF investors own include NVIDIA (NVDA), Broadcom (AVGO), Adobe (ADBE), Arista Networks (ANET), Meta Platforms (META), e.l.f. Beauty (ELF) and General Electric (GE). Fund Details IssuerVirtus Fund NameVirtus LifeSci Biotech Clinical Trials ETF Tax ClassificationRegulated Investment Company Stock ExchangeNYSEARCACurrent SymbolNYSEARCA:BBC Inception Date12/16/2014 Fund ManagerMatthew B. Brown, Seth Kadushin WebN/A PhoneN/AFund Focus Asset ClassEquity BenchmarkLifeSci Biotechnology Clinical Trials Index CategorySector FocusHealth Care Development LevelDeveloped Markets RegionNorth America Number of Holdings122 Fund Statistics Assets Under Management$11.50 million Average Daily Volume$1,933.80 Discount/Premium0.03% Administrator, Advisor and Custodian AdministratorVirtus ETF Solutions, LLC AdvisorVirtus ETF Advisers LLC CustodianThe Bank of New York Mellon Corporation DistributorETF Distributors LLC Transfer AgentThe Bank of New York Mellon Corporation TrusteeN/A Lead Market MakerVirtu Financial Options OptionableOptionable Options Volume1 Put Options1 Call Options1 Short Interest3,400 shs Miscellaneous Outstanding Shares400,004Beta1.22 Creation Unit50,000 Creation Fee$500.00 2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free Report Top 10 BBC HoldingsScholar Rock (NASDAQ:SRRK)Holding Weight: 2.38%Longboard Pharmaceuticals (NASDAQ:LBPH)Holding Weight: 2.30%Summit Therapeutics (NASDAQ:SMMT)Holding Weight: 1.96%Bny Mellon Cash Reserve UsdHolding Weight: 1.88%Wave Life Sciences (NASDAQ:WVE)Holding Weight: 1.76%IGM Biosciences (NASDAQ:IGMS)Holding Weight: 1.69%Edgewise Therapeutics (NASDAQ:EWTX)Holding Weight: 1.48%Viridian Therapeutics (NASDAQ:VRDN)Holding Weight: 1.43%Praxis Precision Medicines (NASDAQ:PRAX)Holding Weight: 1.39%Applied Therapeutics (NASDAQ:APLT)Holding Weight: 1.28%Full Holdings DetailsBBC Sector ExposureBBC Industry Exposure This page (NYSEARCA:BBC) was last updated on 11/5/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredMissed Out On Nvidia?Artificial Intelligence is a tool with the potential to create massive distributions of wealth… In fact, it...Unstoppable Prosperity | Sponsored626 winning trades out of 647…Imagine turning nearly every Friday into a payday. That's exactly what one reclusive multi-millionaire trad...Investing Daily | Sponsored625,000% GainImagine swapping your daily coffee expense for a future free of financial worries. It might seem far-fetche...Crypto Swap Profits | SponsoredWARNING: “Buffett Indicator” flashing for first time in 50 yearsWarren Buffett has sold a staggering $97 billion worth of stocks this year... But why? Our research indi...Behind the Markets | SponsoredCrypto Crash Ahead? (27 Experts Weigh In)Your Portfolio Could Be at RISK Emergency summit reveals crypto could save you!Crypto 101 Media | SponsoredGrab this ETF paying a huge 22% dividendImagine a world where you don't have to stress about inflation eroding your savings... Where your paycheck ...Investors Alley | SponsoredNvidia is Pivoting to Solve Big Tech’s $1 Trillion ProblemTaiwan Semiconductor, a partner of Nvidia’s for more than two decades, has seen its shares explode as much as ...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Virtus LifeSci Biotech Clinical Trials ETF Please log in to your account or sign up in order to add this asset to your watchlist. Share Virtus LifeSci Biotech Clinical Trials ETF With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.